All News

Money and pills

The 10 drugs, spanning disease states from diabetes to heart failure to rheumatoid arthritis, cost Medicare enrollees a total of $3.4 billion in out-of-pocket costs in 2022. As required by the Inflation Reduction Act (IRA), negotiations between Part D and pharmaceutical companies will take place this year and next, with the negotiated prices taking effect in 2026.

Illustrated colorectal image | Credit: mi_viri - stock.adobe.com

Although HER2 amplification showed prognostic capabilities in patients with RAS wild-type metastatic colorectal cancer (mCRC), it was not predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.